Mer­ck lays out vi­sion for wom­en's health spin­out Organon, with some spe­cial plans for its $9B wind­fall

As Mer­ck pre­pares to launch its women’s health spin­off Organon next month, the lead­er­ship teams at both com­pa­nies showed off their busi­ness de­vel­op­ment plans Mon­day. And based on the way Mer­ck tells it, there’s a lot to like for the new­co, even if it’s not quite for them.

Organon’s prod­ucts while as a Mer­ck sub­sidiary ac­count­ed for rough­ly $6.6 bil­lion in 2020 sales, Mer­ck said Mon­day, led by ef­forts in con­tra­cep­tive and biosim­i­lar fran­chis­es. That fig­ure will like­ly stay the same for 2021, falling in the es­ti­mat­ed $6.1 to $6.4 bil­lion range.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.